Droxidopa

A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.

Also Known As:

3,4-threo-DOPS; DL-threo-3,4-Dihydroxyphenylserine; Droxidopa, (DL-Tyr)-Isomer; erythro-3,4-Dihydroxyphenylserine; threo-DOPS; 3,4 Dihydroxyphenylserine; 3,4 threo DOPS; DL threo 3,4 Dihydroxyphenylserine; erythro 3,4 Dihydroxyphenylserine; threo DOPS; 3,4-Dihydroxyphenylserine; L-Tyrosine, beta,3-dihydroxy-, threo-

Networked: 167 relevant articles (29 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hewitt, L Arthur: 15 articles (03/2022 - 01/2014)
2.	Hauser, Robert A: 9 articles (03/2022 - 01/2014)
3.	Biaggioni, Italo: 9 articles (12/2020 - 07/2014)
4.	Kaufmann, Horacio: 9 articles (01/2019 - 03/2008)
5.	Rowse, Gerald J: 7 articles (05/2017 - 08/2016)
6.	Vernino, Steven: 5 articles (11/2018 - 10/2016)
7.	François, Clément: 4 articles (01/2022 - 01/2016)
8.	Shibao, Cyndya A: 4 articles (12/2020 - 01/2019)
9.	Gupta, Fiona: 4 articles (12/2017 - 01/2017)
10.	Karabin, Beverly: 4 articles (12/2017 - 01/2017)

Related Diseases

1.	Orthostatic Hypotension (Postural Hypotension) 01/01/2015 - "Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes of this trial. " 02/01/2015 - "Oral droxidopa was effective in the shorter-term treatment of patients with symptomatic neurogenic orthostatic hypotension, with improvements seen in symptoms, the impact of symptoms on daily activities and standing systolic blood pressure. " 01/01/2016 - "Droxidopa has been approved for the treatment of neurogenic orthostatic hypotension (NOH) under the US Food and Drug Administration accelerated approval program, which warrants confirmatory evidence on long-term efficacy of droxidopa. " 01/01/2016 - "Hereby, we synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of droxidopa for patients with neurogenic orthostatic hypotension. " 09/15/2015 - "In addition, two randomized, placebo-controlled, double-blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. "
2.	Parkinson Disease (Parkinson's Disease) 01/01/2008 - "L-Threo-DOPS has been reported to have a symptomatic beneficial effect in patients with pure freezing syndrome, but small-scale, controlled trials in Parkinson's disease could not support those early observations. " 11/01/2018 - "As the largest subpopulation of patients with nOH has a diagnosis of Parkinson disease (PD), the efficacy and tolerability of droxidopa in patients with PD and nOH were examined using integrated clinical trial data. " 02/01/1998 - "Effects of L-threo-Dops (Dops) administration on orthostatic hypotention were evaluated with changes in blood pressure by postural change (lying to standing position) and subjective symptoms in 15 patients of Parkinson's disease having symptoms of orthostatic hypotention. " 01/01/1997 - "L-threo-DOPS was a poor precursor for NA and also failed to influence extracellular DA in striatum, questioning its use in the treatment of freezing gait in late stages of Parkinson's disease." 10/01/1987 - "The effect of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) on synaptic transmission to the soleus motoneurons was studied using the H-reflex method in 12 normal subjects and in 4 patients with Parkinson's disease. "
3.	Dizziness (Lightheadedness) 01/01/2016 - "The efficacy of droxidopa decreased gradually after 2 weeks, and its statistical significance was lost after 8 weeks (OHQ score MD -0.18, P = 0.61; dizziness/lightheadedness score MD -0.71, P = 0.11; and standing SBP MD 2.96, P = 0.29). " 07/22/2014 - "Improvement in OHQ symptom subscore favored droxidopa by 0.73 units (p = 0.010), with maximum change in "dizziness/lightheadedness." Improvement in symptom-impact subscore favored droxidopa by 1.06 units (p = 0.003), with maximum change for "standing a long time." Mean standing systolic blood pressure (BP) increased by 11.2 vs 3.9 mm Hg (p < 0.001), and mean supine systolic BP by 7.6 vs 0.8 mm Hg (p < 0.001). " 10/01/2016 - "Droxidopa was effective at reducing dizziness [mean difference -0.97 (95% confidence interval -1.51, -0.42)], overall symptoms [-0.52 (-0.98, -0.06)] and difficulty with activity [-0.86 (-1.34, -0.38)]. " 01/01/2014 - "At Week 1, mean dizziness/lightheadedness score change favored droxidopa by 1.5 units (p = 0.24), with subsequent numerical differences favoring droxidopa throughout the observation period, and at Week 1, mean standing systolic blood-pressure change favored droxidopa by 12.5 mmHg (p = 0.04). " 06/15/1992 - "The results were as follows: (1) resting MSA increased significantly 80 min after administration of L-threo-DOPS and was accompanied by an increase in plasma NE levels; (2) standing MSA when treated with the drug was not significantly different from values obtained under control conditions; and (3) MSA responsiveness to orthostasis was reduced after L-threo-DOPS. "
4.	Hypertension (High Blood Pressure) 03/01/2021 - "This post hoc study examined changes in SBP in patients receiving droxidopa (100-600 mg, three times daily) during a 12-month long-term extension study based on whether patients had supine hypertension (ie, supine SBP ≥140 mmHg) at baseline. " 05/12/2017 - "Supine hypertension rates were low, but slightly higher in patients receiving droxidopa (≤7.9% vs ≤4.6% for placebo); patients with severe hypertension at screening were excluded from these studies. " 08/01/2001 - "L-threo-DOPS was well tolerated, with the 2 serious adverse events reported being a possible complication of the disease under study, and with no reports of supine hypertension. " 03/01/2021 - "There was no consistent or progressive elevation in supine SBP over time during the 12-month treatment with droxidopa in patients either with or without supine hypertension at baseline. " 03/01/2021 - "After 12 months of droxidopa treatment, patients with supine hypertension at baseline had a mean supine SBP decrease of 3 mmHg and a mean standing SBP increase of 9 mmHg. "
5.	Multiple System Atrophy 03/01/1999 - "We evaluated the effect of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) on the response of blood pressure and vasoactive factors during head-up tilt in patients with multiple system atrophy (MSA). " 01/01/2017 - "Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy." 07/22/2014 - "Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization (100-600 mg 3 times daily), followed, in responders, by 7-day washout and then a 7-day double-blind trial of droxidopa vs placebo. " 08/01/2001 - "This study was designed to determine the efficacy and tolerability of increasing doses of L-threo-dihydroxyphenylserine (L-threo-DOPS) in treating symptomatic orthostatic hypotension associated with multiple system atrophy (MSA) and pure autonomic failure (PAF). " 01/01/1991 - "Treatment with L-threo-3,4-dihydroxyphenylserine (L-threo-dops), a synthetic precursor of norepinephrine, significantly increased upright blood pressure in patients with multiple system atrophy but had no effect on the upright blood pressure of patients with pure autonomic failure. "

Related Drugs and Biologics

1.	Norepinephrine (Noradrenaline)
2.	Droxidopa
3.	Levodopa (L Dopa)
4.	Dopamine (Intropin)
5.	Midodrine (Midon)
6.	Prodrugs
7.	Amino Acids
8.	Enzymes
9.	Aromatic-L-Amino-Acid Decarboxylases
10.	Pyridostigmine Bromide (Pyridostigmine)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Activities of Daily Living (ADL)
4.	Polypharmacy
5.	Heart Transplantation (Grafting, Heart)